Methylphenidate and thinking tests in children with intellectual disability and ADHD
Tests whether a thinking test detects methylphenidate effects in children with intellectual disability and ADHD.
Key facts
- Who runs it
- University of California, Davis
- Where
- Chicago, Cincinnati, and Sacramento, United StatesSee the 3 sites
- Trial code
- Registry title
- Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
- Status
- Enrolling by invitation
- Phase
- Phase 1
- People taking part
- 68 people, planned
- Started
- 1 Feb 2023
- Planned end
- 29 Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methylphenidate Oral Solution
- Record updated
- 15 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for young people with intellectual disability and ADHD. It tests whether a thinking-skills test battery (NIHTB-CB) picks up changes with methylphenidate compared with placebo.
- Age
- 6 Years to 24 Years
- Sex
- All sexes can join
- Disease stage
- Diagnosis of intellectual disability and of ADHD. IQ below 80 and mental age 3.0 or higher (Stanford Binet). Must be able to complete valid NIHTB-CB tests at screening/baseline.
- Earlier treatment
- No stimulant use within 2 weeks before randomization.
Main reasons for not taking part
- Past sensitivity reaction to stimulants
- Stimulant use within 2 weeks before randomization
- Serious other psychiatric or medical illness that makes stimulants unsafe, such as uncontrolled epilepsy, bipolar disorder, psychosis, severe OCD, high blood pressure, fast heart rate or failure to thrive
- Someone in the household with a current substance abuse disorder
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- IQ below 80
- Mental age 3.0 or higher (Stanford Binet)
- Diagnosis of Intellectual Disability
- Diagnosis of ADHD
- Ability to complete valid NIHTB-CB tests at screening/baseline
Who cannot take part
- stimulant use within 2 weeks prior to randomization
- history of a sensitivity reaction to stimulants
- presence of significant comorbid psychiatric or medical disorder/illness deemed by the site physician as inappropriate for stimulant use (uncontrolled epilepsy, bipolar disorder, psychosis, severe OCD, hypertension, tachycardia hypertension, failure to thrive, psychosis for example)
- a household resident with a current substance abuse disorder
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 24 years old?
Where in United States
- RUSH UniversityChicago, United StatesEnrolling by invitation
- Cincinnati Children's HospitalCincinnati, United StatesEnrolling by invitation
- UC Davis MIND InstituteSacramento, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This study is a randomized, double-blind, placebo-controlled, crossover trial of extended-release liquid methylphenidate (XRMPH) to evaluate the sensitivity of the NIH Toolbox Cognition Battery (NIHTB-CB) to changes in cognition in children and adolescents ages 6 to 17 with intellectual disability (D) and comorbid Attention Deficit Hyperactivity Disorder (ADHD). The sample will include 68 males or females (expected male: female ratio of 1.8:1 with ID and ADHD as determined by structured diagnostic interview and Conners 3 scores. Additional inclusion criteria will include Full Scale IQ above 50 and mental age greater than or equal to 3 years. In addition, participants must be able to complete NIHTB-CB testing and provide valid scores at baseline. After baseline testing, participants will then be randomized to drug or placebo in a 1:1 ratio (N=34 per group) at the end of the baseline visit. XRMPH in oral suspension supplied as Quillivant XR in 5 mg/ml (Tris Pharma, Monmouth Junction, NJ) will be the active treatment. The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth). The Clinical Global Impression (CGI) will be used as a guide to define optimal dose. If side effects occur the dose will be reduced to the dose level at which there were no side effects. Final optimal dose will be established by the end of week 3 and this will be maintained for 2 weeks until 5 weeks post randomization, at which time the follow-up parent and teacher Conners scales, NIHTB-CB, Go/No-Go, and PedsQL will be completed. Participants will have a washout period of 1 week, will then complete re-assessment at the second baseline, and then will cross over to the other treatment (Quillivant to placebo; placebo to Quillivant), also in a double-blind fashion. In the second treatment arm, patients will have the same titration, monitoring and treatment periods as in the first arm, again followed by repeated assessments at the conclusion of 5 weeks. The accrual of participants and number of visits is shown in the Timeline per 6-month period.
The 2 groups in the trial
- MethylphenidateExisting treatment, for comparison
Treatment: Methylphenidate Oral Solution
- PlaceboPlacebo, for comparison
Treatment: Methylphenidate Oral Solution
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Sensitivity of the NIH Toolbox Cognition Battery to Stimulant Treatment in Intellectual Disabilities
- Plain-language title
- Methylphenidate and thinking tests in children with intellectual disability and ADHDGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05301361, who can take part
- Record updated
- 15 December 2025